VALABREGA, Giorgio
 Distribuzione geografica
Continente #
NA - Nord America 4.808
EU - Europa 2.343
AS - Asia 1.970
OC - Oceania 114
AF - Africa 63
SA - Sud America 55
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.359
Nazione #
US - Stati Uniti d'America 4.575
CN - Cina 1.117
IT - Italia 709
GB - Regno Unito 361
FR - Francia 267
DE - Germania 257
CA - Canada 197
JP - Giappone 183
IN - India 127
VN - Vietnam 115
ES - Italia 106
AU - Australia 99
KR - Corea 90
NL - Olanda 87
HK - Hong Kong 73
PL - Polonia 58
IE - Irlanda 55
BE - Belgio 54
RU - Federazione Russa 52
TR - Turchia 48
FI - Finlandia 41
CZ - Repubblica Ceca 40
TW - Taiwan 38
CH - Svizzera 37
ZA - Sudafrica 35
MX - Messico 34
DK - Danimarca 33
SE - Svezia 27
MK - Macedonia 26
RO - Romania 24
SG - Singapore 23
BR - Brasile 22
TH - Thailandia 21
ID - Indonesia 20
AT - Austria 19
PT - Portogallo 19
UA - Ucraina 18
IL - Israele 17
IR - Iran 17
NO - Norvegia 17
NZ - Nuova Zelanda 15
AE - Emirati Arabi Uniti 14
PH - Filippine 14
CL - Cile 13
NG - Nigeria 10
MY - Malesia 9
PK - Pakistan 9
SA - Arabia Saudita 9
AR - Argentina 8
CO - Colombia 7
EG - Egitto 6
LT - Lituania 6
BA - Bosnia-Erzegovina 5
PE - Perù 5
AP - ???statistics.table.value.countryCode.AP??? 4
GR - Grecia 4
HR - Croazia 4
HU - Ungheria 4
KW - Kuwait 4
AM - Armenia 3
IS - Islanda 3
MA - Marocco 3
OM - Oman 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
UG - Uganda 3
BD - Bangladesh 2
ET - Etiopia 2
IQ - Iraq 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
TN - Tunisia 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BJ - Benin 1
BT - Bhutan 1
BY - Bielorussia 1
CU - Cuba 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
KH - Cambogia 1
MD - Moldavia 1
NP - Nepal 1
PR - Porto Rico 1
TG - Togo 1
Totale 9.359
Città #
Fairfield 422
Houston 325
Ashburn 284
Beijing 229
Seattle 225
Santa Cruz 218
Woodbridge 211
Buffalo 209
Cambridge 166
Ann Arbor 156
Columbus 132
Wilmington 128
Shanghai 115
Ottawa 108
Dong Ket 82
Torino 77
Chicago 70
Chengdu 63
Guangzhou 63
Wuhan 62
London 56
New York 52
Simi Valley 50
Turin 50
Nanjing 49
Tokyo 49
Changsha 46
Dublin 46
Los Angeles 40
University Park 39
Pisa 38
Milan 37
Rome 37
Las Vegas 36
San Diego 36
Warsaw 36
Hangzhou 33
Shenyang 33
Boardman 29
Chongqing 29
Muizenberg 29
Duncan 28
Dallas 26
Bengaluru 25
Taipei 25
Helsinki 23
Clearwater 22
Seoul 22
Central 21
Toronto 21
Phoenix 20
San Jose 20
Amsterdam 19
Changchun 19
Mountain View 19
Central District 18
Jinan 18
Nagareyama 18
San Francisco 18
Lake Forest 15
Sydney 15
Berlin 14
Des Moines 14
Dundee 14
Sheffield 13
Singapore 13
Vienna 13
Copenhagen 12
Henderson 12
Izmir 12
Jakarta 12
Lappeenranta 12
Madrid 12
Melbourne 12
Nanchang 12
Padova 12
Zhengzhou 12
Council Bluffs 11
Hanoi 11
Nottingham 11
Philadelphia 11
Redmond 11
Atlanta 10
Bangkok 10
Frankfurt am Main 10
Lexington 10
Manchester 10
Nürnberg 10
Paris 10
Portland 10
Rochester 10
Xian 10
Detroit 9
Fuzhou 9
Genoa 9
Hefei 9
Leawood 9
Naples 9
Provo 9
Silver Spring 9
Totale 5.035
Nome #
PARP Inhibitors in Ovarian Cancer, file e27ce42f-ad3d-2581-e053-d805fe0acbaa 2.367
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions, file e27ce429-ba9f-2581-e053-d805fe0acbaa 508
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome, file e27ce42f-f839-2581-e053-d805fe0acbaa 480
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer, file e27ce42f-d9bd-2581-e053-d805fe0acbaa 344
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy, file e27ce426-ac70-2581-e053-d805fe0acbaa 343
Metastatic breast cancer subtypes and central nervous system metastases., file e27ce426-f2c2-2581-e053-d805fe0acbaa 283
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer, file e27ce42b-163a-2581-e053-d805fe0acbaa 260
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer?, file e27ce429-b1f4-2581-e053-d805fe0acbaa 249
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity, file e27ce42c-a76a-2581-e053-d805fe0acbaa 247
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer, file e27ce42a-da57-2581-e053-d805fe0acbaa 237
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?, file e27ce42b-59b1-2581-e053-d805fe0acbaa 220
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers, file e27ce42f-be83-2581-e053-d805fe0acbaa 165
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy, file e27ce427-fb48-2581-e053-d805fe0acbaa 163
Androgen receptor status predicts development of brain metastases in ovarian cancers, file e27ce42c-05d1-2581-e053-d805fe0acbaa 156
Recent advances in the development of breast cancer vaccines., file e27ce427-0b7e-2581-e053-d805fe0acbaa 151
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis, file e27ce430-45cf-2581-e053-d805fe0acbaa 149
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer, file e27ce426-fd7a-2581-e053-d805fe0acbaa 146
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer., file e27ce429-b730-2581-e053-d805fe0acbaa 137
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer, file ed30a300-d9fe-4ce9-83e8-d76fcb4d73b0 137
Adoptive immunotherapy against ovarian cancer, file e27ce429-4f51-2581-e053-d805fe0acbaa 132
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells, file e27ce435-09ce-2581-e053-d805fe0acbaa 130
Role of cyclin-dependent kinase inhibitors in endometrial cancer, file e27ce42f-f83c-2581-e053-d805fe0acbaa 129
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers, file e27ce42d-d5ef-2581-e053-d805fe0acbaa 128
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications, file e27ce42e-cec0-2581-e053-d805fe0acbaa 114
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience, file e27ce430-2b28-2581-e053-d805fe0acbaa 108
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21), file e27ce434-d9c6-2581-e053-d805fe0acbaa 103
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents., file e27ce42d-e147-2581-e053-d805fe0acbaa 96
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy, file e27ce42e-0aba-2581-e053-d805fe0acbaa 96
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer, file e27ce42c-bace-2581-e053-d805fe0acbaa 94
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience, file e27ce42c-d5e9-2581-e053-d805fe0acbaa 94
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy, file e27ce431-cc2b-2581-e053-d805fe0acbaa 93
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells., file e27ce42f-6b49-2581-e053-d805fe0acbaa 92
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer, file e27ce430-12da-2581-e053-d805fe0acbaa 92
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma, file e27ce42f-58bf-2581-e053-d805fe0acbaa 87
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy, file e27ce430-3de5-2581-e053-d805fe0acbaa 87
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report, file e27ce42e-fddd-2581-e053-d805fe0acbaa 86
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas, file e27ce42f-d57d-2581-e053-d805fe0acbaa 86
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey, file e27ce434-e28a-2581-e053-d805fe0acbaa 84
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells, file e27ce42e-d784-2581-e053-d805fe0acbaa 77
Ovarian cancer immunotherapy: Turning up the heat, file e27ce42f-f83b-2581-e053-d805fe0acbaa 75
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience, file e27ce42f-d57f-2581-e053-d805fe0acbaa 73
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives, file e27ce42f-d57e-2581-e053-d805fe0acbaa 68
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors, file e27ce434-d591-2581-e053-d805fe0acbaa 65
Is there a role for immunotherapy in ovarian cancer?, file e27ce42f-cca2-2581-e053-d805fe0acbaa 64
Translational research in ovarian cancer, file e27ce431-4297-2581-e053-d805fe0acbaa 58
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality, file e27ce435-1099-2581-e053-d805fe0acbaa 57
Immunotherapy in cervix cancer, file e27ce434-c204-2581-e053-d805fe0acbaa 49
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group, file e27ce435-0df0-2581-e053-d805fe0acbaa 40
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey, file e27ce435-855a-2581-e053-d805fe0acbaa 29
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?, file e27ce435-6fd0-2581-e053-d805fe0acbaa 25
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs), file e27ce42e-de99-2581-e053-d805fe0acbaa 24
Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report, file 7c224205-7e98-4dfa-80b5-5f8745410fab 20
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition, file e27ce435-a799-2581-e053-d805fe0acbaa 20
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study, file e3009967-8951-4d63-ac33-d2369dd472c6 19
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups, file e27ce434-feca-2581-e053-d805fe0acbaa 18
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia, file 0803831b-13e7-4b14-b95e-e2b3b03de2d5 16
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study, file 5947a685-bb1f-47be-89be-fbfb095ba792 16
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy, file e27ce434-f492-2581-e053-d805fe0acbaa 16
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers, file e4d8c451-e503-4043-a58b-c8bd8446711a 15
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w), file e27ce434-c166-2581-e053-d805fe0acbaa 14
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature, file e27ce435-83c1-2581-e053-d805fe0acbaa 13
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, file 5aea012d-a6d0-42f4-a6e4-7603180689b0 11
Biomarkers of central nervous system involvement from epithelial ovarian cancer, file e27ce434-ce4f-2581-e053-d805fe0acbaa 9
Veliparib: a new therapeutic option in ovarian cancer?, file e27ce42e-2c92-2581-e053-d805fe0acbaa 8
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22), file 62c3d437-a1d4-4fda-b997-b8fbad23d912 7
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study, file 8de7f72e-fb7f-4db1-8fe0-2b690271564c 7
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs), file e27ce42e-cf86-2581-e053-d805fe0acbaa 7
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer, file e27ce427-3a76-2581-e053-d805fe0acbaa 5
Searching for prognostic markers for Stage I epithelial ovarian cancer: A role for systemic inflammatory markers, file 339364dd-b4ab-47de-92ff-e2d0033eb01a 4
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience, file 8f2258b7-dc9a-4e76-8ba8-6e3673949448 4
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors, file be64f5a3-0826-412c-9a03-2f74dc5a7cb9 4
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib, file e27ce426-c5d7-2581-e053-d805fe0acbaa 4
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis, file 2d154b6e-d8ce-40a0-8917-c4a35289612e 3
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma, file 9109526f-b862-4655-954f-22b3a0e3b56e 2
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer., file e27ce426-e99b-2581-e053-d805fe0acbaa 2
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer, file e27ce428-f629-2581-e053-d805fe0acbaa 2
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design, file 74015b5d-d65b-496a-8315-bbd6a05f9fd6 1
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study, file a62bf83e-59ba-4b84-a22d-786d11fa5680 1
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers, file a70e325d-eb14-4f04-90bc-359b3e602db8 1
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study, file c1f29fbf-cbd3-4df8-9e6e-63d89c33963a 1
Multitarget drugs: the present and the future of cancer therapy, file e27ce426-b5ec-2581-e053-d805fe0acbaa 1
Potential of afatinib in the treatment of patients with HER2-positive breast cancer., file e27ce426-f44e-2581-e053-d805fe0acbaa 1
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series, file e27ce42c-e4ca-2581-e053-d805fe0acbaa 1
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models, file e27ce42e-de9a-2581-e053-d805fe0acbaa 1
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature, file e27ce431-e586-2581-e053-d805fe0acbaa 1
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer, file e27ce432-5e86-2581-e053-d805fe0acbaa 1
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society, file e61348dc-dc5a-4282-8e44-1333c59647d7 1
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial, file f0db6949-f933-42dd-aae1-b89ab48ec607 1
Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features, file f6cf104e-22e7-4433-8f90-34c31a3d57c3 1
Totale 9.636
Categoria #
all - tutte 15.379
article - articoli 0
book - libri 0
conference - conferenze 277
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.656


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019240 0 0 0 0 0 0 0 0 0 0 141 99
2019/2020848 72 68 56 121 61 47 56 85 120 46 51 65
2020/20212.148 79 208 242 137 163 199 154 144 159 228 190 245
2021/20222.719 239 199 158 331 279 154 216 192 228 170 365 188
2022/20231.654 82 126 314 236 139 106 136 117 168 98 103 29
2023/2024854 26 44 89 80 73 68 104 112 29 64 165 0
Totale 9.636